cas 4334-88-7|| where to buy (4-Ethoxycarbonylphenyl)boronic acid

Produktname:(4-Ethoxycarbonylphenyl)boronic acid

IUPAC Name:[4-(ethoxycarbonyl)phenyl]boronic acid

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM135619-100g	in stock	ƦƦț

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 4334-88-7 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:4334-88-7; Molekulare Formel:C9H11BO4; Schmelzpunkt:-; SMILES-Code:C1=C(C(OCC)=O)C=CC(=C1)B(O)O; Dichte:

: Katalognummer:CM135619; Molekulargewicht:193.99; Siedepunkt:; Mdl-Nr.:MFCD02179441; Lagerung:

: Boronic Acids and Esters; Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).; Boronic Acid For Sale; Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

: Momelotinib; GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.